Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response

CompletedOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

September 3, 2022

Study Completion Date

September 3, 2022

Conditions
Hepatitis C Virus (HCV)
Trial Locations (10)

125310

Infectious Clinical Hosp #1 /ID# 225063, Moscow

142007

LLC Center of Targeted Therapy /ID# 239529, Domodedovo

190103

Saint-Petersburg AIDS Center /ID# 239357, Saint Petersburg

302038

S. P. Botkin City Hospital /ID# 229510, Oryol

350000

Specialized Clinical Infectious Diseases Hospital /ID# 229814, Krasnodar

355017

Stavropol State Medical University /ID# 243216, Stavropol

443029

Samara Region Clinical HIV/AIDS Prevention and Control Center /ID# 226591, Samara

454048

South Ural State Medical University /ID# 226555, Chelyabinsk

603022

Infectious Clinical Hospita l#2 /ID# 243217, Nizhny Novgorod

664035

Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 229509, Irkutsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY